There has been a recent emergence of novel minimally invasive surgical therapies (MIST) for the treatment of benign prostatic hyperplasia (BPH). Prostatic urethral lift (PUL, Urolift) and transurethral water vapor therapy (TWVT, Rezum) are performed in the ambulatory setting and offer superior preservation of sexual function and less risk of retrograde ejaculation. Aquablation offers short treatment time, fewer sexual side effects, and possible same-day hospital discharge. As each of these technologies has gained rapid adoption, we identified a need for further evaluation of procedural complications in broader clinical practice.